Bridge Laboratories is a US-owned, preclinical contract research organization (CRO) that provides US-level regulatory compliant drug development services globally. Bridge is headquartered in Gaithersburg, Maryland, with lab facilities in the US and Beijing, China. Bridge is known for its extensive work in toxicology; including vaccines, developmental and reproductive toxicology, and safety pharmacology. Bridge’s AAALAC accredited facility in China was among the first labs to perform GLP studies for clients worldwide.
Bridge differs from other CROs by being extremely flexible and customer-centric, with an innovative spirit and “can-do” attitude that begins with top management and carries through all employees in all departments. Bridge’s high number of experienced staff also ensures that their clients consistently get the top study directors working on their projects. Bridge employees take pride in being professional, yet accessible; knowledgeable, yet always looking for innovative ideas and new ways to serve their customers.
This attitude translates to a working relationship between Bridge and its clients that involves consistent, two-way communication and attention to every detail. Thus Bridge is able to provide clients with rapid study start scenarios, dynamic scheduling options to meet key client milestones, high quality studies and reports, flexibility and accessibility throughout the process, and on-time follow-through with results. Bridge delivers value through the combination of reasonable pricing and the highest quality services.
Last Updated: 01-22-2008